Genedx (WGS) Stock
Clinical genetic testing company for rare disease diagnostics. Here's the price, business snapshot, and what's worth knowing about Genedx in October 2026.
GeneDx Holdings Corp (WGS) is a clinical genetic testing company that offers diagnostic genomic services for rare disease, hereditary conditions and other specialised indications. With a market capitalisation of about $3.50 billion, the business derives revenue from laboratory testing, interpretation services and partnerships with clinicians and biopharma. Investors should note the company operates in a fast-evolving field: wider adoption of genomic testing and advances in sequencing can support growth, while reimbursement policies, competition and regulatory scrutiny can affect margins and volume. Key considerations include the company’s ability to scale testing, protect patient data, manage costs of technology and secure favourable payer coverage. As with most healthcare and diagnostics stocks, shares can be volatile and long-term outcomes depend on clinical utility, commercial execution and the regulatory environment. This summary is educational and not investment advice; investors should assess suitability for their own situation and consider consulting a financial adviser.
Genedx (WGS) Stock Forecast
Analyst price target, next 12 months
$81.55
+32.4% vs today's $61.60
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Genedx have a consensus 12-month target of $81.55, above the current price of $61.60.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying GeneDx's stock, expecting it to rise significantly in value.
Financial Health
GENEDX is performing well with strong revenue, cash flow, and profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Growing testing demand
Increasing clinical acceptance of genomic testing could support volume growth, though reimbursement and payer coverage remain important constraints.
Technology and scale
Sequencing and data analytics can be differentiators if the company scales efficiently, but R&D and equipment costs may pressure margins.
Regulation and access
International expansion and partnerships offer opportunity, yet regulatory variation and data‑privacy rules can complicate market access.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
